pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Anzupgo
drug · small molecule
save

delgocitinib

Marketedupdated 3mo ago
by Leo Pharma AS🔗 ChEMBL
Approved
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 4 investigational indications.

targets

Janus Kinase (JAK)

all catalysts(0)

nothing on the calendar yet

Trials studying delgocitinib

  • phase3A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosusrecruitingn=652
  • phase2A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosisrecruitingn=135
  • phase2Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilarisrecruitingn=30
  • phase3Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczemacompletedn=98
  • phase3A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczemacompletedn=362
  • phase3A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczemacompletedn=513
  • phase3Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trialscompletedn=801
  • phase3Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczemacompletedn=487
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Jul 23, 2030
~3.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (1)

  • Sep 19, 2031compositionUS 8609647

FDA exclusivities (1)

  • Jul 23, 2030NCENew Chemical Entity (5y)3.9y

News(1)

  • LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drug
    This is the third recent acquisition conducted by Denmark’s LEO Pharma in medical dermatology, a portfolio that marked 12% growth in the first half of the year.
    biospace · 2d ago
brand
Anzupgo
generic
delgocitinib
MOA
Janus Kinase (JAK) inhibitor
indication
Hand Dermatitis
phase
marketed
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 9m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?